Clinical trial
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ…
NCT00003518 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003518 |
|---|---|
| Title | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors |
| Official title | Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Testicular Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, paclitaxel |
| Enrollment | 44 |
| Start date | Jan 25, 1999 |
| Primary completion | Jul 1, 2002 |
| First posted | May 24, 2004 |
| Last update posted | Jun 22, 2023 |
| Countries | South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: